Efficacy and safety of direct oral anticoagulants vs vitamin K antagonists in patients with atrial fibrillation and end-stage renal disease on hemodialysis: A systematic review and meta-analysis
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Efficacy and safety of direct oral anticoagulants vs vitamin K antagonists in patients with atrial fibrillation and end-stage renal disease on hemodialysis: A systematic review and meta-analysis
Authors
Keywords
-
Journal
European Journal of Internal Medicine
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2023-08-28
DOI
10.1016/j.ejim.2023.08.020
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Direct Oral Anticoagulants Versus Warfarin Across the Spectrum of Kidney Function: Patient-Level Network Meta-Analyses From COMBINE AF
- (2023) Josephine Harrington et al. CIRCULATION
- Correct dosing, adherence and persistence of DOACs in atrial fibrillation and chronic kidney disease: a systematic review and meta-analysis
- (2023) Subo Emanuel et al. Open Heart
- Direct Oral Anticoagulants in Patients on Chronic Dialysis and Concomitant Atrial Fibrillation: A Common Clinical Impasse
- (2022) Nikolaos Ktenopoulos et al. Frontiers in Bioscience - Scholar
- A Randomized Controlled Trial Comparing Apixaban With the Vitamin K Antagonist Phenprocoumon in Patients on Chronic Hemodialysis: The AXADIA-AFNET 8 Study
- (2022) Holger Reinecke et al. CIRCULATION
- Apixaban for Patients With Atrial Fibrillation on Hemodialysis: A Multicenter Randomized Controlled Trial
- (2022) Sean D. Pokorney et al. CIRCULATION
- 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation
- (2021) Jan Steffel et al. EUROPACE
- Effectiveness and safety of rivaroxaban versus warfarin in Taiwanese patients with end-stage renal disease and nonvalvular atrial fibrillation: A real-world nationwide cohort study
- (2021) Yi-Cheng Lin et al. PLoS One
- The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
- (2021) Matthew J Page et al. BMJ-British Medical Journal
- Multitargeted interventions to reduce dialysis-induced systemic stress
- (2021) Bernard Canaud et al. Clinical Kidney Journal
- Rivaroxaban versus apixaban in non‐valvular atrial fibrillation patients with end‐stage renal disease or receiving dialysis
- (2020) Benjamin Miao et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
- (2019) Craig T. January et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Benefits and Harms of Oral Anticoagulant Therapy in Chronic Kidney Disease
- (2019) Jeffrey T. Ha et al. ANNALS OF INTERNAL MEDICINE
- RoB 2: a revised tool for assessing risk of bias in randomised trials
- (2019) Jonathan A C Sterne et al. BMJ-British Medical Journal
- Multicenter Randomized Controlled Trial of Vitamin K Antagonist Replacement by Rivaroxaban with or without Vitamin K2 in Hemodialysis Patients with Atrial Fibrillation: the Valkyrie Study
- (2019) An S. De Vriese et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Outcomes Associated with Apixaban Use in End-Stage Kidney Disease Patients with Atrial Fibrillation in the United States
- (2018) Konstantinos C. Siontis et al. CIRCULATION
- Oral Anticoagulation in Patients With End-Stage Kidney Disease on Dialysis and Atrial Fibrillation
- (2018) Austin Hu et al. SEMINARS IN NEPHROLOGY
- Warfarin and Vascular Calcification
- (2016) Timothy J. Poterucha et al. AMERICAN JOURNAL OF MEDICINE
- Pharmacokinetics, Pharmacodynamics, and Safety of Single-Dose Rivaroxaban in Chronic Hemodialysis
- (2016) Clapton Dias et al. AMERICAN JOURNAL OF NEPHROLOGY
- ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions
- (2016) Jonathan AC Sterne et al. BMJ-British Medical Journal
- ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions
- (2016) Jonathan AC Sterne et al. BMJ-British Medical Journal
- Dose-Finding Study of Rivaroxaban in Hemodialysis Patients
- (2015) An S. De Vriese et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Dabigatran and Rivaroxaban Use in Atrial Fibrillation Patients on Hemodialysis
- (2015) K. E. Chan et al. CIRCULATION
- Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis
- (2015) Xiaoli Wang et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Edoxaban versus Warfarin in Patients with Atrial Fibrillation
- (2013) Robert P. Giugliano et al. NEW ENGLAND JOURNAL OF MEDICINE
- Systematic review and meta-analysis of incidence, prevalence and outcomes of atrial fibrillation in patients on dialysis
- (2012) D. Zimmerman et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Bleeding and thrombotic complications of kidney disease
- (2011) Sue Pavord et al. BLOOD REVIEWS
- The Increasing Prevalence of Atrial Fibrillation among Hemodialysis Patients
- (2011) W. C. Winkelmayer et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Apixaban versus Warfarin in Patients with Atrial Fibrillation
- (2011) Christopher B. Granger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
- (2011) Manesh R. Patel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dabigatran versus Warfarin in Patients with Atrial Fibrillation
- (2009) Stuart J. Connolly et al. NEW ENGLAND JOURNAL OF MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started